• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » What Patients Are Saying About Antipsychotic [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

What Patients Are Saying About Antipsychotic [60 Sec Psych]

September 9, 2020

In the early 1990’s, half of US patients with bipolar disorder took lithium. Now it’s closer to 15%, and the use of antipsychotics has more than doubled to fill the gap. A new survey reveals what patients think about these newcomers. [Link]


Published On: 9/9/2020


Duration: 2 minutes, 49 seconds


Transcript:

In the early 1990’s, half of US patients with bipolar disorder took lithium. Now it’s closer to 15%, and the use of antipsychotics has more than doubled to fill the gap. A new survey reveals what patients think about these newcomers.

This was an online survey of 200 US adults who – by their self report – were diagnosed with bipolar I disorder and had taken an antipsychotic within the past year. Aripiprazole was the most common, followed by quetiapine (52%), risperidone (37%), olanzapine (29%), and lurasidone (24%). Overall, people were satisfied with the efficacy but dissatisfied with the tolerability.

98% had at least one side effect, and most of the side effects were not trivial. 92% felt the side effects had a negative impact on their relationships. Patients were embarrassed by the side effects, particularly anxiety, weight gain, followed by involuntary spasms or movements and trouble concentrating. I’m reminded of Dr. Mago’s warning in our June 2019 issue on side effects that patients are not likely to put up with a side effect they find embarrassing.

The ones that bothered people the most were anxiety, weight gain, and feeling like a zombie or having no emotions – and the rates of these 3 burdensome effects were in the 70% range. 

Antipsychotic side effects carried over into all areas of life – family, romance, friendships, and job performance. 30-50% felt the antipsychotic impacted their job, while 60-70% felt the bipolar symptoms impacted their job

The bottom line: While the PDR can tell us what side effects to expect, surveys like this tell us just how damaging those side effects are. And the numbers here are much higher than what’s reported in the PDR. What’s unclear is whether lithium or the anticonvulsants would raise the same level of complaint. In last Monday’s podcast we reviewed more encouraging survey data for lamotrigine and lithium, and next month we’ll feature a review of mood stabilizer tolerability in our online journal.

Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.